Replies to post #103767 on Biotech Values

[DewDiligence]

ZGEN/BMY—They already are, but don't let that get in the way of the argument.

Then you should have no trouble telling us exactly who is making consequential money selling interferon for HBV and how much they are making. I’m anxiously awaiting your reply. (Hint: Don’t waste time looking at Roche and MRK; each of them is on record that their interferon sales for HBV are de minimis.)

Like I said, this is all a moot point.

Actually, the discussion is germane insofar as your credibility is at issue. I think your contention that ZGEN shareholders are being shortchanged by BMY’s buyout is total BS, but I can see why you would want to maintain such a posture.